You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies will bundle claims analytics, clinical decision support, provider education, and other pharmacist-driven support for prescribers.
The available data suggests PGx may be useful in managing medications for COVID-19 patients and in helping people struggling with the mental health impact of the pandemic.
The Helsinki-based firm is making its panel available for free to people who already have been genotyped by consumer genomics services or biobanks.
The precision medicine center at Colorado's UCHealth expects to add 100,000 participants annually and have 17 drug-gene pairs for pharmacogenomics this year.
The EHR vendor is re-engineering its architecture to increase interoperability with genetic labs and merge genomic and pathology information at the point of care.
Regulators told the lab industry that they can continue to offer PGx lab tests without FDA approval if they make evidence-based claims.
With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.
The agency compiled the evolving list by drawing on information from drug labeling and the published literature and is asking stakeholders to provide feedback.
The companies will join their respective technologies to provide pharmacogenomic information for patients undergoing genetic testing.
Consumers have filed complaints about the San Diego-based firm's questionable business practices and lack of response in the last year.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.